Jane Street’s Aprea Therapeutics APRE Stock Holding History

Jane Street’s Portfolio APRE Stock Details APRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,240	Closed	-$127K	–	10005
2021 Q3	$127K	Buy	+1,240	New	+$113K	﹤0.01%	9158

Other funds holding APRE

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SRL

Scientech Research LLC Jersey City, New Jersey $120M AUM 73.62% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jane Street's APRE Position: Q1 2026 in Review

Jane Street sold out of Aprea Therapeutics (APRE) in Q1 2026, closing a stake of 46,621 shares — an estimated $39.8K sold.

Jane Street first reported a position in APRE in Q4 2020 and held it in 6 quarters. The position peaked at $72K in Q3 2021. 22 funds tracked by Wall St. Rank hold APRE as of Q1 2026.

Jane Street reported no remaining Aprea Therapeutics position as of Q1 2026 after selling out during the quarter.
Jane Street sold 46,621 Aprea Therapeutics shares in Q1 2026, an estimated $39.8K.
Jane Street first reported a position in Aprea Therapeutics in Q4 2020 and held it in 6 quarters.
Jane Street's Aprea Therapeutics position peaked at $72K in Q3 2021.
22 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.